Braveheart Inv Regulatory News (BRH)

23 April 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Operational update on certain strategic investments

Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to provide a further operational update on Kirkstall Limited and Pharm 2 Farm Limited within the context of the COVID-19 pandemic.

Kirkstall Limited ("Kirkstall") (holding 64.67%)

Kirkstall is now collaborating with Animal Free Research UK, the UK's leading non-animal medical research charity, awarding grants to research scientists to implement new and existing techniques to replace the use of animal in trials and research.

During the week commencing 27 April 2020, Animal Free Research UK will launch a call for proposals from UK universities centred around the use of the QuasiVivo technology for research relating to COVID-19. To support this programme, Kirkstall will provide QuasiVivo cell test chambers without charge to research teams selected by Animal Free Research UK, together with technical support to those teams from Kirkstall's founder Dr Malcolm Wilkinson. Dr Williamson has accepted an invitation to sit on the assessment panel to decide which project proposals have most merit.

Carla Owen, CEO of both Animal Free Research UK and its Scientific Advisory Panel, will consider research proposals including diagnostic tests, lung disease and associated drug testing, related to COVID-19, from UK universities centred around the use of the QuasiVivo technology. This collaboration will enable research teams to respond quickly and use their skills to help understand how to treat this virus and the QuasiVivo system helps to minimise the need for animal trials.

Pharm 2 Farm Limited ("P2F") (holding 51.72%)

As previously announced, P2F is currently manufacturing medical grade alcohol hand sanitiser gel. In response to demand relating to the COVID-19 pandemic P2F is now planning to increase production to 2000 litres per day by the end of May. In addition to supplying the NHS, P2F are have begun supplying local care homes.

The P2F scientific team are also exploring whether further items of PPE can be designed and sourced to meet the requirements of the medical sector, should current conditions persist beyond the Summer.

For further information: